Epstein Becker Green and EBG Advisors presented a webinar series that examined the average manufacturer price (“AMP”) Final Rule and its effect on drug pricing and contracting.
The long-awaited issuance of the Final Rule addressing AMP under the Medicaid Drug Rebate Program provided clarity in some respects but left other issues open to interpretation. In the wake of the Final Rule, other regulatory developments showed signs of further impacting many of the same issues.
Using the AMP Final Rule as a baseline, presenters addressed the evolution of some of the most significant issues affecting drug pricing and contracting.
In this session, Dr. Samuel R. Nussbaum, M.D., Strategic Consultant at EBG Advisors, and Lesley R. Yeung, Associate at Epstein Becker Green, examined the pay-for-value and alternative approaches to pharmaceutical pricing. The speakers discussed opportunities and barriers as well as highlight real-world examples.